Fulcrum Therapeutics (FULC) Research & Development (2020 - 2025)
Historic Research & Development for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to $14.3 million.
- Fulcrum Therapeutics' Research & Development fell 234.31% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.6 million, marking a year-over-year decrease of 2410.71%. This contributed to the annual value of $63.4 million for FY2024, which is 1171.99% down from last year.
- Latest data reveals that Fulcrum Therapeutics reported Research & Development of $14.3 million as of Q3 2025, which was down 234.31% from $13.0 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Research & Development registered a high of $25.0 million during Q2 2022, and its lowest value of $11.7 million during Q4 2024.
- Moreover, its 5-year median value for Research & Development was $17.3 million (2021), whereas its average is $17.2 million.
- In the last 5 years, Fulcrum Therapeutics' Research & Development soared by 4396.94% in 2022 and then plummeted by 3834.94% in 2024.
- Quarter analysis of 5 years shows Fulcrum Therapeutics' Research & Development stood at $18.9 million in 2021, then decreased by 1.83% to $18.6 million in 2022, then grew by 2.33% to $19.0 million in 2023, then plummeted by 38.35% to $11.7 million in 2024, then increased by 22.05% to $14.3 million in 2025.
- Its Research & Development stands at $14.3 million for Q3 2025, versus $13.0 million for Q2 2025 and $11.7 million for Q4 2024.